Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 2
2003 2
2004 4
2005 1
2006 6
2007 6
2008 2
2009 7
2010 3
2011 10
2012 11
2013 8
2014 12
2015 11
2016 15
2017 14
2018 11
2019 15
2020 12
2021 17
2022 18
2023 14
2024 6
2025 9
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

192 results

Results by year

Filters applied: . Clear all
Page 1
Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis.
Lee KC, Wu PS, Lin HC. Lee KC, et al. Clin Mol Hepatol. 2023 Jan;29(1):77-98. doi: 10.3350/cmh.2022.0237. Epub 2022 Oct 13. Clin Mol Hepatol. 2023. PMID: 36226471 Free PMC article. Review.
The initial presentation of non-alcoholic steatohepatitis (NASH) is hepatic steatosis. The dysfunction of lipid metabolism within hepatocytes caused by genetic factors, diet, and insulin resistance causes lipid accumulation. ...Increased leptin …
The initial presentation of non-alcoholic steatohepatitis (NASH) is hepatic steatosis. The dysfunction of lipid metabol …
Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD).
Qiu YY, Zhang J, Zeng FY, Zhu YZ. Qiu YY, et al. Pharmacol Res. 2023 Jun;192:106786. doi: 10.1016/j.phrs.2023.106786. Epub 2023 May 3. Pharmacol Res. 2023. PMID: 37146924 Free article. Review.
Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of disease phenotypes which start with simple steatosis and lipid accumulation in the hepatocytes - a typical histological lesions characteristic. ...Thiazolidinediones (TZD …
Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of disease phenotypes which start …
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; NASH CRN. Sanyal AJ, et al. N Engl J Med. 2010 May 6;362(18):1675-85. doi: 10.1056/NEJMoa0907929. Epub 2010 Apr 28. N Engl J Med. 2010. PMID: 20427778 Free PMC article. Clinical Trial.
BACKGROUND: Nonalcoholic steatohepatitis is a common liver disease that can progress to cirrhosis. Currently, there is no established treatment for this disease. ...Serum alanine and aspartate aminotransferase levels were reduced with vitamin E and with pi …
BACKGROUND: Nonalcoholic steatohepatitis is a common liver disease that can progress to cirrhosis. Currently, there is no esta …
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Cusi K, Orsak B, Bril F, Lomonaco R, Hecht J, Ortiz-Lopez C, Tio F, Hardies J, Darland C, Musi N, Webb A, Portillo-Sanchez P. Cusi K, et al. Ann Intern Med. 2016 Sep 6;165(5):305-15. doi: 10.7326/M15-1774. Epub 2016 Jun 21. Ann Intern Med. 2016. PMID: 27322798 Clinical Trial.
MEASUREMENTS: The primary outcome was a reduction of at least 2 points in the nonalcoholic fatty liver disease activity score in 2 histologic categories without worsening of fibrosis. ...Pioglitazone treatment also was associated with improvement in in …
MEASUREMENTS: The primary outcome was a reduction of at least 2 points in the nonalcoholic fatty liver disease activity …
Comparative effectiveness of multiple different treatment regimens for nonalcoholic fatty liver disease with type 2 diabetes mellitus: a systematic review and Bayesian network meta-analysis of randomised controlled trials.
Deng M, Wen Y, Yan J, Fan Y, Wang Z, Zhang R, Ren L, Ba Y, Wang H, Lu Q, Fan H. Deng M, et al. BMC Med. 2023 Nov 16;21(1):447. doi: 10.1186/s12916-023-03129-6. BMC Med. 2023. PMID: 37974258 Free PMC article.
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) are closely related and mutually contribute to the disease's development. ...Referring to the lower surface under the cumulative ranking curves (SUCRA) and the lea …
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) are closely related and mutual …
Pioglitazone in the treatment of NASH: the role of adiponectin.
Gastaldelli A, Harrison S, Belfort-Aguiar R, Hardies J, Balas B, Schenker S, Cusi K. Gastaldelli A, et al. Aliment Pharmacol Ther. 2010 Sep;32(6):769-75. doi: 10.1111/j.1365-2036.2010.04405.x. Aliment Pharmacol Ther. 2010. PMID: 20662773 Clinical Trial.
Pioglitazone increased 2.3-fold plasma adiponectin and improved insulin resistance, glucose tolerance and glucose clearance, steatosis and necroinflammation (all P < 0.01-0.001 vs. placebo). ...CONCLUSIONS: Adiponectin exerts an important metabolic role at …
Pioglitazone increased 2.3-fold plasma adiponectin and improved insulin resistance, glucose tolerance and glucose clear …
A gut microbial metabolite of linoleic acid ameliorates liver fibrosis by inhibiting TGF-beta signaling in hepatic stellate cells.
Kasahara N, Imi Y, Amano R, Shinohara M, Okada K, Hosokawa Y, Imamori M, Tomimoto C, Kunisawa J, Kishino S, Ogawa J, Ogawa W, Hosooka T. Kasahara N, et al. Sci Rep. 2023 Nov 3;13(1):18983. doi: 10.1038/s41598-023-46404-5. Sci Rep. 2023. PMID: 37923895 Free PMC article.
The antidiabetic drug pioglitazone ameliorates insulin resistance by activating the transcription factor PPARgamma. In addition to its blood glucose-lowering action, pioglitazone exerts pleiotropic effects including amelioration of nonalcoholic fatt …
The antidiabetic drug pioglitazone ameliorates insulin resistance by activating the transcription factor PPARgamma. In …
Efficacy and safety of dapagliflozin compared to pioglitazone in diabetic and non-diabetic patients with non-alcoholic steatohepatitis: A randomized clinical trial.
Abdel Monem MS, Adel A, Abbassi MM, Abdelaziz DH, Hassany M, Raziky ME, Sabry NA. Abdel Monem MS, et al. Clin Res Hepatol Gastroenterol. 2025 Mar;49(3):102543. doi: 10.1016/j.clinre.2025.102543. Epub 2025 Jan 29. Clin Res Hepatol Gastroenterol. 2025. PMID: 39884573 Clinical Trial.
BACKGROUND: Non-alcoholic steatohepatitis (NASH) is a serious end-stage spectrum of non-alcoholic fatty liver disease (NAFLD) with associated high risk of hepatic and extrahepatic complications. ...There was a significant in …
BACKGROUND: Non-alcoholic steatohepatitis (NASH) is a serious end-stage spectrum of non-alcoholic fatt …
Treatment of Metabolic (Dysfunction)-Associated Fatty Liver Disease: Evidence from Randomized Controlled Trials-A Short Review.
Kitsios K, Trakatelli CM, Antza C, Triantafyllou A, Sarigianni M, Kotsis V. Kitsios K, et al. Metab Syndr Relat Disord. 2024 Dec;22(10):703-708. doi: 10.1089/met.2024.0059. Epub 2024 Aug 1. Metab Syndr Relat Disord. 2024. PMID: 39088384 Review.
Metabolic-associated fatty liver disease (MALFD) is a highly prevalent and progressive disease, strongly related to obesity, metabolic syndrome, and cardiovascular disease. ...Moreover, substantial weight loss after bariatric surgery can lead to …
Metabolic-associated fatty liver disease (MALFD) is a highly prevalent and progressive disease, strongly related …
[PPAR and NASH].
Tanaka N, Aoyama T. Tanaka N, et al. Nihon Rinsho. 2006 Jun;64(6):1089-94. Nihon Rinsho. 2006. PMID: 16768114 Review. Japanese.
Recently, it has been recognized that PPAR also modulates inflammatory responses, regulates cell division and associates with liver fibrogenesis and tumorigenesis. Although the roles of PPAR for the pathogenesis of nonalcoholic steatohepatitis (NASH) remain unclear, …
Recently, it has been recognized that PPAR also modulates inflammatory responses, regulates cell division and associates with liver f …
192 results